Although many cancer prognoses have improved in the past fifty years due to advancements in treatments, there has been little to no improvement in therapies for small cell lung cancer (SCLC) which currently has a five-year survival rate of less than 7%. One promising avenue to improve treatment for SCLC is to understand its underlying genetic alterations that drive its formation and growth. One such mutation in SCLC, which appears in many cancers, is of the Rb gene. When mutated, Rb causes hyperproliferation and loss of cellular identity. Normally Rb promotes differentiation by regulating lineage specific transcription factors including regulation of pluripotency factors such as Sox2. However, there is evidence that when certain tissues lose Rb, Sox2 becomes upregulated and promotes oncogenesis. To better understand the relationship between Rb and Sox2 and to uncover new treatments for SCLC we have studied the role of Sox2
Introduction
Small cell lung cancer (SCLC) is a devastating disease where survival rates are typically measured in 2-year segments, rather than the typical 5. Its low rate of detection at early stages is exacerbated by its ability for rapid metastasis and almost invariable resistance to therapy (1) .
Patients who are stricken by this disease face a 6% 2-year survival rate while most will succumb less than a year after diagnosis (2) . Despite this alarming statistic, the standard of care for treating SCLC has remained essentially the same for the past 40 years and few innovations have been developed. Patients still rely on platinum-based drugs that are not ideal because of their lack of precision. Just as researchers have found new drugs for many other cancers based on their DNA mutations, scientists have looked for new drugs to treat SCLC. In the pursuit of these new therapies, researchers begin by seeking to understand the underlying genetic causes of SCLC.
As in many other cancers, the retinoblastoma protein (Rb) is lost in SCLC (6) (7) (8) (9) (10) (11) (12) . Normally Rb is recognized for its responsibility in the regulation of the cell cycle but it also interacts with many lineage-specific transcription factors (1) . One of the transcription factors regulated by Rb is Sox2 (2) . Known primarily as a pluripotency factor, Sox2 is also a key master regulator of neural and neuroendocrine cell types (3) (4) (5) (6) (7) . As a master regulator, Sox2 influences cell identity early and widely in the cell fate decisions. Pulmonary neuroendocrine cells are a common cell of origin for SCLC, therefore is possible that Sox2 activity in neuroendocrine cells following Rb loss induces stem or progenitor genetic networks that help to drive oncogenesis. To that end, we generated a conditional knockout mouse in which we could perturb Sox2 activity in a SCLC mouse model to assess the consequence of SCLC formation after Sox2 loss. We observed that Sox2 is indeed required for SCLC formation, validating Sox2 as an oncogenic driver of SCLC.
Experimental Methods

Ethics statement
Mice were maintained according to the guidelines set for the by the NIH and were housed in the Sanford Research Animal Research Center, accredited by AAALAC using protocols reviewed by our local IUACUC.
SCLC mouse tumor initiation
We modeled SCLC in the Rb lox/lox , p53 lox/lox , p130 lox/lox , Rosa luc mouse line (8) . Sox2 +/+ , +/lox , and lox/lox . To study SCLC tumor initiation, we injected Cre-recombinase adenovirus (Baylor Vector Core) into the mouse lungs by intratracheal injection to excise the floxed genes. The mice were assigned to either a six-month cohort, a three-month cohort or the survival curve. Mouse lungs, livers, and any tumors were harvested for immunohistochemistry.
SCLC cell lines
We used the murine SCLC cell lines KP1 and KP3 and the human SCLC lines NJH29 (H29) and NCI-H82 (H82) (8, 9) . The cells were maintained in suspension and cultured in RPMI with 10% bovine growth serum and penicillin/streptomycin.
SCLC lung and liver immunohistochemistry
The Sanford Research Pathology Core performed the immunohistochemistry for this study. The mouse lungs, livers and tumors were stained with H&E, for Sox2, calcitonin (Sigma, 38198 1:2,000), anti-phospho-histone H3 (EMD Millipore 06-570 1:500), cleaved caspase 3 (CST-9664 1:100), ki67.
Tissue image analysis and statistics
We used Cell Profiler to count the tumors unbiasedly and to determine whether they are CGRP+ to identify them as SCLC over another kind of cancer.
Lentiviral and siRNA transfection
We made the lentivirus using the packaging plasmids VSVG, pMDL, and RSV in 293T cells.
Virus was concentrated and titired for reproducible transductions. We measure their viability after the knock down with an alamar blue assay, and the levels of apoptosis with Annexin V and flow cytometry. qPCR was used to confirm the knock down of Sox2 in the cells.
Results
To investigate if Sox2 is required for the formation of SCLS, we bred a mouse line containing a conditional Sox2 allele (Sox2 lox/lox ) to an existing mouse models for SCLC. This mouse, consisting of Rb lox/lox ; p130 lox/lox ; p53 lox/lox ; Rosa26 LSL-Luciferase alleles, displays all the hallmarks of human SCLC, mainly the same histological characteristics, rapid metastasis, and chemoresistance (8, 10, 11) . To overcome the dramatic effects of Rb-and p53-loss in the mouse, we localized Cre-mediated recombination to the lung by the intratracheal instillation of a Creexpressing adenovirus (Adeno-Cre). Due to the presence of the floxed p130 allele (8), we observed early tumors around 3-months, with a robust tumor burden 6-months after Crerecombination ( Figure 1 ).
We bred this SCLC mouse line with a Sox2 lox/lox line, ensuring that we generated mice of all three potential Sox2 genotypes: Sox2 +/+ , Sox2 +/lox , and Sox2 lox/lox . By this strategy, we can determine if one or both alleles of Sox2 may be involved in SCLC formation. Tumors were initiated by Adeno-Cre, and as expected Rb; p53; p130 mice showed a sizeable number of tumor foci showing the histological characteristics of SCLC 6 months after Cre infection ( Figure  2 ) (8, 12) . The Rb; p53; p130; Sox2 mice had a nearly complete loss of SCLC foci observed at the same timepoint (Figure 2A,B ). We observe a significant lengthening of the lifespan of the Rb; p53; p130; Sox2 mice ( Figure 2C ). Finally, to fully characterize these tumors and ensure Sox2 loss in the Rb; p53; p130; Sox2 mice, we have optimized immunohistochemistry staining and an unbiased image analysis pipeline to identify and characterize these tumors to perform thorough statistical analysis of the Rb; p53; p130; Sox2 + tumors compared to the few Rb; p53; p130; Sox2 tumors ( Figures 2D and 2E) .
Indeed, of the few tumors Rb; p53; p130; Sox2 tumors, a plurality showed immunoreactivity to Sox2 antibodies, indicating that they are the result of incomplete Cre function. However, a small number of Rb; p53; p130; Sox2 tumors appeared to be Sox2 indicating that Sox2 activity may not be necessary in some SCLC tumors.
To investigate the requirement for the Rb-Sox2 axis in the growth and maintenance of already established tumors, murine cell lines for SCLC were infected with adenovirus harboring Rb and a GFP reporter (Adeno-Rb-GFP) or GFP alone (Adeno-GFP). After sorting for GFP + cells, the SCLC cell lines showed reduction of Sox2 upon overexpression of Rb ( Figure 3A ). As Rb overexpression in mouse SCLC will slow the growth of established tumors (13) , we sought to determine if knockdown of Sox2 would have deleterious effects on the cancer cells. Indeed, we observed that short hairpin-mediated knockdown of Sox2 (shSox2) achieve a ~60-90% knockdown by RT-qPCR ( Figure 3B ) and resulted in an increase in cell death ( Figure 3C ). Sox2 knockdown also dramatically reduced the growth of both mouse and human SCLC cell lines ( Figure 3D ).
Discussion
Sox2 is an essential transcription factor, and has been observed to be misregulated in various cancer of the epithelium. As a cancer that rises from the lung epithelium, it seemed reasonable that Sox2 may indeed be a driver of SCLC (12) . Furthermore, we had previously observed that Rb specifically binds to and repressed the core pluripotency network, including Sox2 (2). As SCLC is initiated in part, by loss of Rb it was possible that Rb-loss resulted in Sox2 upregulation, which might drive SCLC (10, 14, 15) . Indeed, SCLC oftentimes shows amplification of Sox2 (14) . Therefore, this data and others shows that Sox2 activity is indeed a driver of SCLC (14) .
We did, however, observe a small minority of Rb; p53; p130; Sox2 tumors. Whether these tumors were indeed independent of Sox2 activity, or if they received signaling from the microenvironment which activated Sox2 target genes in the absence of Sox2 is currently unclear.
One potential interesting facet of SCLC biology is the realization that it is not a homogenous disease; rather it is characterized by four different subtypes (16) . The Rb lox/lox ; p130 lox/lox ; p53 lox/lox mouse model predominantly gives rise to the most prevalent subtype of SCLC, SCLC-A (17) . SCLC-A is characterized by strong expression of the neural bHLH transcription factor, Ascl1 (18, 19) . In neural cells, Ascl1 is a direct target of Sox2 (20) (21) (22) . Therefore, in SCLC, a neuroendocrine tumor, Sox2 activity may upregulate Ascl1. Sox2 may therefore may bridge the loss of Rb and Ascl1. However, the exact mechanism that Sox2 may have in the regulation of Ascl1, or in the major genetic determinants of the other SCLC subtypes is currently unclear.
What these results do indicate is that Sox2 is required for SCLC, and may in the future may be a potential biomarker or therapeutic target towards the treatment of this devastating disease. 
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